Pediatrix Medical Group, Inc.
NYSE•MD
CEO: Mr. Mark S. Ordan
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 1995-09-20
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
連絡先情報
時価総額
$1.67B
PER (TTM)
9.9
16.2
配当利回り
--
52週高値
$24.99
52週安値
$11.84
52週レンジ
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$493.77M+0.00%
直近4四半期の推移
EPS
$0.40+0.00%
直近4四半期の推移
フリーCF
$108.82M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Net Income Rebounds Strongly Net income reached $165.4M in 2025, reversing $99.1M loss in 2024; same-unit revenue grew 6.2%.
Operations Swing to Profitability Income from operations was $208.8M (10.9% margin) in 2025, a major improvement from $68.7M loss last year.
Strategic Acquisitions Completed Acquired multiple practices including maternal-fetal and neonatology groups during 2025, expanding core specialty footprint.
Cash Position Significantly Improved Cash and equivalents increased to $375.2M by year-end 2025, up $145.3M from prior year levels.
リスク要因
Medicaid Reimbursement Uncertainty Reimbursement relies heavily on GHC Programs; state budgetary constraints and reform efforts pose ongoing adverse effects.
Past Goodwill Impairment Risk Recorded $150.6M non-cash goodwill impairment in 2024 due to sustained stock price decline; future risk remains.
Litigation and Malpractice Exposure Inherent risk from malpractice claims; self-insurance reserves are subject to complex actuarial estimates and potential shortfalls.
Declining US Birth Rates Future patient volumes face risk from declining US birth rates, potentially impacting revenue growth across services.
見通し
Focus on Core Specialty Growth Strategy centers on hospital-based and maternal-fetal medicine; exited office-based practices finalized in 2024.
Technology Integration Efforts Continued investment in technology like BabySteps, achieving initial HITRUST certification for core clinical applications.
Managing Debt Structure Total debt principal reduced to $596.9M by 2025; managing variable rate debt exposure remains key focus.
Operational Efficiency Improvements Transformation efforts target reducing administrative expenses and improving revenue cycle management efficiency post-outsourcing.
同業比較
売上高 (TTM)
$6.32B
$6.22B
$5.45B
粗利益率 (最新四半期)
165.5%
82.9%
67.7%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| LFST | $2.47B | 252.9 | 0.7% | 8.8% |
| NHC | $2.42B | 20.1 | 11.6% | 5.7% |
| ACHC | $2.23B | -2.0 | -39.4% | 48.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.5%
緩やかな成長
4四半期純利益CAGR
17.5%
収益性の大幅な改善
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月30日
EPS:$0.38
|売上高:$466.75M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし